"The UK committee has concluded its investigations and recommended to the Medicines Health Regulatory Authority (MHRA) that trials in the UK are safe to resume". The vaccine has been administered to about 25 volunteers at JSS Hospital in the phase two trials that began on August 29.
Earlier in the day, AstraZeneca resumed clinical trials of its vaccine, developed jointly with the University of Oxford following a brief suspension after one of the participants suffered a side effect last week, causing transverse myelitis, an inflammation of spinal cord. This vaccine is now under Phase III of the clinical trial and the Chinese military is presently using this vaccine to vaccinate its soldiers.
Amid question of full indemnification by some pharma companies from any risks from their vaccines by purchasing countries, Dmitriev clarified that Russian Federation will not follow such approach as it has demonstrated the safety and efficiency of its human adenoviral vector platform, including its Sputnik V vaccine.
"The independent review process has concluded and following the recommendations of both the independent safety review committee and the United Kingdom regulator, the MHRA, the trials will recommence in the United Kingdom".
"In large trials illnesses will happen by chance but must be independently reviewed to check this carefully", the University of Oxford had said in an official statement. Six other leading Covid-19 vaccine candidates are also in this final phase, according to the World Health Organization. Overseas trials have been expanded in regard to ethnicity, countries, and larger populations, and most importantly, they have been recognized by global community, which is very good for future applications, he said. "We will back our scientists to deliver an effective vaccine as soon as safely possible", he wrote on Twitter.
Following the announcement, AstraZeneca Japan is considering resuming vaccine trials in Japan.
The AZD1222, formerly known as ChAdOx1 nCoV-19, is a weakened form of the common cold virus that has been genetically moderated so that it can not grow in humans.
The vaccine produced by Moderna had shown good results in monkeys against the coronavirus and was first inducted into human trials in March this year, yielding promising results.
Last month, the Ministry of Health of Russian Federation registered a coronavirus vaccine, which was dubbed "Sputnik V" after the Soviet-era satellite that was the first launched into space in 1957, becoming the world's first registered vaccine against COVID-19. News that the trial is resuming comes four days after the disclosure that it had been paused because of a suspected serious adverse reaction in a participant.